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Abstract
Retinal vasculopathy with cerebral leukodystrophy (RVCL) is a rare, autosomal dominant 
condition caused by mutations of the three-prime repair exonuclease-1 (TREX1). The phenotypic 
expressions range from isolated retinal involvement to varying degrees of retinopathy, cerebral 
infarction with calcium depositions, nephropathy, and hepatopathy. We report a case of RVCL 
caused by a novel TREX1 mutation. This patient’s multisystem presentation, retinal involvement 
interpreted as “retinal vasculitis”, and improvement of neuroimaging abnormalities with 
dexamethasone led to the accepted diagnosis of a rheumatologic disorder resembling Behçet’s 
disease. Clinicians should consider RVCL in any patient with retinal capillary obliterations 
associated with tumefactive brain lesions or nephropathy.
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Case Presentation (Dr. Cory Perugino)
A 44-year-old man was admitted to another hospital with visual field defects, intermittent 
confusion, apraxia, extinction to double simultaneous stimulation on the left, and mild left-
sided weakness. For two days prior to admission, he had been confused, unable to recall 
recent events and execute certain actions, such as tying his shoes.
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His medical history was complex. Retinal vasculopathy and chronic kidney disease of 
unclear etiology had been diagnosed in Germany six years prior to admission. Hypertension 
was diagnosed a year later, followed by hypertensive cardiomyopathy approximately two 
years after the onset of visual symptoms. The retinal vasculopathy had been termed posterior 
uveitis with retinal vasculitis. Over the succeeding six years, the patient had been treated 
with several immunosuppressive medications, including prednisone, cyclosporine, 
mycophenolate mofetil, adalimumab, methotrexate, and interferon-alpha. Additional 
treatments included laser photocoagulation, intravitreal glucocorticoids, and bevacizumab. 
Five months before admission, he developed acute heart failure, headache, and visual field 
defects, and all treatments had been discontinued.
The patient had undergone two kidney biopsies in the years before this hospitalization, at 
four years and then again at three years before admission. Both of these biopsies had been 
interpreted as thrombotic microangiopathy affecting the interlobular arteries and afferent 
arterioles with focal segmental glomerulosclerosis and mild nephrosclerosis. No 
tubulointerstitial disease was present.
He underwent extensive diagnostic studies, including evaluations of the blood and 
cerebrospinal fluid (CSF), computed tomography (CT) of the head, brain magnetic 
resonance imaging (MRI), and a whole-body 18F-fluorodeoxyglucose positron emission 
tomography/computed tomography (FDG-PET/CT) study. The initial non-contrast MRI of 
the brain revealed a tumefactive lesion in the right temporo-parieto-occipital area with 
confluent T2/fluid-attenuated inversion recovery (FLAIR) signal abnormalities extending 
through the splenium of the corpus callosum into the left periventricular white matter (Fig 
1A). An additional T2 hyperintense white matter lesion was noted in the left cerebellar 
hemisphere. Scattered punctate areas of restricted diffusion [hyperintense areas on diffusion-
weighted imaging (DWI) with corresponding apparent diffusion coefficient (ADC) 
hypointensities] were present in the right parietal lobe (Fig 1B).
The CT scan of the brain demonstrated focal calcifications in the right frontal, left frontal, 
and right parietal white matter (Fig 1C). Review of a head CT scan obtained for evaluation 
of headaches 2 years earlier revealed no abnormalities. A head CT that had been obtained 
five months before admission for evaluation of the headache and the visual field defects 
reportedly showed multiple punctate areas of calcification with surrounding vasogenic 
edema in the right superior frontal gyrus. That imaging study was not available for review.
Whole-body FDG-PET/CT imaging showed no evidence of lymphadenopathy or 
malignancy. Laboratory investigations were remarkable only for abnormalities in renal 
function. The serum creatinine was 3.1 mg/dL (normal <1.3 mg/dL), and a urinalysis 
revealed 2+ proteinuria, several dysmorphic red blood cells (RBCs), and a few granular casts 
in the urine sediment. The CSF analysis documented total nucleated cell counts of 1 and 5 
cells/µL (normal <6 cells/µL), a total CSF protein of 58 mg/dL (normal 5–55 mg/dL), and 
CSF glucose of 64 mg/dL. The CSF IgG index was 0.39 (normal <0.77), and angiotensin 
converting enzyme (ACE) level was 1.2 U/L (normal <2.5 U/L).
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The patient then underwent a biopsy of the right hemispheric lesion. This revealed markedly 
abnormal white matter but no definite diagnosis. A second biopsy, performed two weeks 
later, was similarly interpreted as being non-diagnostic.
High-dose dexamethasone was initiated for extensive cerebral edema noted on imaging. 
After five weeks at the outside hospital, the patient was transferred to our institution for 
further management.
The patient was a molecular biologist who had lived for many years in Germany and France. 
He drank alcohol moderately and did not smoke. He was married but had no children. The 
patient’s father died aged 36 years from Hodgkin’s lymphoma and his paternal uncle died in 
his early forties from an unclear cause accompanied by renal dysfunction. The family 
history on his mother’s side was unremarkable. The patient denied any history of oral, 
genital, or skin lesions, sicca symptoms, musculoskeletal, respiratory or gastrointestinal 
symptoms.
On examination, the patient was afebrile with an irregularly irregular pulse at a rate of 98 
beats per minute and blood pressure of 146/98 mmHg. The respiratory rate was 14 per 
minute. There were no cardiac murmurs. The mouth, lung, abdominal, skin, and joint 
examinations were unremarkable. He had 3+ pitting edema of the lower extremities. The 
corrected visual acuity was reduced to 20/80 in the right eye and 20/50-1 in the left eye, with 
bilateral dyschromatopsia. A relative afferent pupillary defect was not present. A dilated 
ophthalmoscopic examination showed dehemoglobinized blood in the left inferior vitreous, 
moderate bilateral symmetric optic atrophy, epiretinal membranes, cotton wool spots in the 
peripapillary area, retinal arteriole obstructions with sclerosis and resulting ghost vessels 
that were most obvious around the optic discs. Extensive pan-retinal photocoagulation scars 
were present bilaterally. Neurological examination on admission was remarkable for non-
specific visual field defects on confrontation testing, mild left lower facial weakness, mild 
left pronator drift, and unsteady gait. Confusion, apraxia, and extinction to double 
simultaneous stimulation on the left, documented five weeks earlier were no longer present.
Table 1 shows the patient’s routine laboratory results upon transfer to our hospital and the 
results of similar examinations obtained 4 years, 3 years, and 5 weeks before the transfer. A 
skin pathergy test, performed at our institution, was negative.
Fluorescein angiography revealed extensive retinal ischemia with enlargement of the foveal 
avascular zones, perivascular fluorescein leakage, hyperfluorescence of vessel walls, and 
numerous scars from pan-retinal photocoagulation (Fig 2). The perivascular leakage of the 
contrast and the hyperfluorescence of vessel walls were repeatedly interpreted as retinal 
vasculitis.
High-dose dexamethasone was continued and weekly adalimumab was added 8 weeks after 
the onset of neurological symptoms, with the working diagnosis of Behçet’s disease. After a 
10-week course of dexamethasone, complete resolution of the mass effect and decrease in 
the extent of the T2 hyperintensity within the cerebral hemispheres was noted on brain MRI 
(Fig 4). However, the patient’s visual acuity continued to deteriorate and there was persistent 
perivascular leakage with retinal ischemia documented by fluorescein angiography.
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The brain biopsies were reviewed. A laboratory test was requested.
Neuropathological Discussion (Dr. Tessa Hedley-Whyte)
The original slides of the renal biopsies were unavailable for review. The brain biopsies were 
markedly abnormal with areas of circumscribed pallor. There was little or no tissue reaction 
surrounding areas of necrosis and extensive calcium deposition (Fig 3A). PAS and elastic 
stains highlighted thickened vessel walls (Fig 3B, C) but otherwise demonstrated no specific 
abnormalities. Adjacent to the areas of necrosis, several angiomatoid vascular proliferations 
associated with a mild, chronic, T cell-predominant inflammatory infiltrate were present 
(Fig 3D). Neurofilament staining revealed loss of axons and axonal spheroid formations 
within the lesions. The lesions seemed to be ischemic but the lack of tissue response was 
reminiscent of the necrosis seen in radiation damage. Although the small vessels were 
abnormal with thickened vessel walls, there was no evidence of vasculitis or arteriosclerosis.
Discussion (Dr. Ivana Vodopivec)
This is a very important and instructive case from many perspectives. I am aware of the 
diagnosis as I was involved in this patient’s care and obtained the confirmatory laboratory 
test. I will discuss the case by applying the logic followed while caring for this patient. First, 
I will address the working diagnosis and other initial differential considerations in a 
systematic manner, from the perspective of the history, the physical examination, the 
available diagnostic evaluations and their interpretations. I will then proceed to discussing 
the underlying pathophysiology and the treatment that we offered to the patient.
To summarize, this is a 44-year-old man who presented with two days of right frontal and 
parietal lobe dysfunction stemming from the tumefactive lesion involving almost the entire 
right hemisphere. Since age 38, he had suffered from progressive retinal vasculitis refractory 
to numerous immunosuppressive medications and chronic kidney disease. The hypertension 
developed a year after the renal insufficiency had been noted, and eventually resulted in 
hypertensive cardiomyopathy complicated by paroxysmal atrial fibrillation. Five months 
prior to the presentation, headache had developed and triggered the neuroimaging that 
demonstrated unexplained right frontal lobe vasogenic edema associated with punctate 
calcifications.
We initially considered two broad categories of neurological disease: immune-mediated, 
related to the suspected “uveitis”; and infectious, particularly those caused by opportunistic 
pathogens.
The retinal vasculopathy in combination with tumefactive cerebral lesions raised the 
possibility of Behçet’s disease. This chronic systemic inflammatory disease, characterized 
by variable-vessel vasculitis,2 is a common cause of posterior uveitiswith retinal vasculitis. 
Behçet’s disease typically causes mucocutaneous lesions, including oral and genital 
ulcerations. In addition, papulopustular and nodular skin lesions, the latter of which mimics 
erythema nodosum, frequently occur in Behçet’s disease. Less common manifestations 
include arthralgias, venous and arterial thrombosis, epididymitis, cardiac (e.g., pericarditis 
or myocarditis), gastrointestinal lesions that mimic Crohn’s disease, and a variety of central 
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nervous system pathologies that often affect the white matter. Parenchymal lesions, some 
with mass effect as seen in this case, are among the most common manifestations of neuro-
Behçet’s disease.3 In the absence of biomarkers, the definitive diagnosis is established using 
clinical criteria that include the presence of recurrent oral ulcerations plus two of the 
following: recurrent genital ulcerations, skin lesions, eye lesions, and a positive pathergy 
test.4 Oral aphthous ulcers are often regarded as a sine qua non of Behçet’s disease.5 In a 
small minority of patients, however, obvious oral ulcerations are observed only after the 
disease has become manifest in other organs. Thus, absolute insistence on oral aphthous 
ulcers before rendering a diagnosis of Behçet’s disease can lead to diagnostic errors. Genital 
aphthous ulcers, which have the same clinical appearance as the oral lesions, occur in about 
80% of patients. The absence of both oral and genital lesions despite lengthy follow-up and 
frequent questioning over this time period made the diagnosis of Behçet’s disease 
improbable. Does the additional diagnostic testing support the diagnosis of Behçet’s 
disease? No. Both the pathergy test and a test for HLA-B51 were negative. However, the 
pathergy test has low sensitivity that is reduced further by immunosuppressive treatments.6, 7 
HLA-B51, the strongest genetic susceptibility factor for Behçet’s disease,8 is present in only 
59% of patients. Its absence, therefore, does not exclude the diagnosis. The patient’s renal 
disease was also difficult to link with a diagnosis of Behçet’s disease. Renal involvement in 
Behçet’s disease is unusual and, when present, occurs years after initial symptoms, rather 
than as the initial presentation. The renal disease observed most commonly in Behçet’s 
disease is secondary amyloidosis,9 but the renal biopsies had not suggested that diagnosis. In 
summary, the patient’s clinical presentation, the negative pathergy and HLA-B51 antigen 
testing, the nature of his renal disease, and the apparent absence of treatment response all 
argued against Behçet’s disease.
The patient’s kidney biopsies suggested a thrombotic microangiopathy and focal segmental 
glomerulosclerosis. One cause of thrombotic microangiopathy is thrombotic 
thrombocytopenic purpura (TTP). TTP can be associated with both central nervous system 
disease (strokes) as well as renal dysfunction.10 Yet the patient’s time course for TTP is 
improbable and he had none of the other classic features of TTP: fever, thrombocytopenia, 
and purpura.
Sarcoidosis is on the differential diagnosis for any patient with simultaneous retinal and 
cerebral manifestations, especially in the setting of retinal vasculitis. Parenchymal 
neurosarcoidosis infrequently presents with mass lesions accompanied by calcifications.11 
The definitive diagnosis is made by tissue biopsy. The histopathological changes observed in 
this case of a microvasculopathy in the absence of granulomatous inflammation excluded 
sarcoidosis.
The diagnosis of tubulointerstitial nephropathy and uveitis (TINU) syndrome was suspected 
early in the course. TINU presents with bilateral acute anterior (rather than posterior) 
uveitis, often in children (median age 15 years).12 Although our patient had both ocular and 
renal dysfunction, the details of his case were incompatible with the diagnosis of TINU.
Granulomatosis with polyangiitis (GPA) is an anti-neutrophil cytoplasmic antibody 
(ANCA)-associated small vessel vasculitis with predilection for the respiratory tract and 
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kidneys. Common ocular manifestations include necrotizing scleritis and orbital 
inflammatory disease.13 The cerebral vessels are involved in 3–5% patients. At least two 
features argued against this diagnosis in our patient: the radiographic findings of 
leukoencephalopathy with tumefactive lesions14, 15 and the repeatedly negative ANCA.
Eales’ disease is an inflammatory venous occlusive disorder of peripheral retina resulting in 
retinal angiogenesis and vitreous hemorrhage.16 It is typically associated with tuberculous 
infection and/or hypersensitivity. Only rare case reports of simultaneous or sequential 
cerebral abnormalities in Eales’ disease exist, and Eales’ disease would not account for the 
patients’ end-stage renal disease.17
Diagnostic possibilities were also broadened by considering opportunistic infections in light 
of the chronic immunosuppression. Toxoplasmosis and progressive multifocal 
leukoencephalopathy were refuted based on the analysis of the serum and the CSF.
It became apparent that none of the aforementioned potential diagnoses discussed truly 
explained the patient’s retinal, renal, and brain parenchymal disease. We therefore re-visited 
the assumptions surrounding the case and re-examined the available pieces of clinical 
information devoid of their interpretations.
Returning to the diagnostic evaluations, it was noteworthy that the fluorescein angiogram 
was interpreted consistently as “retinal vasculitis” over the patient’s entire course across 
multiple hospitals. The brain histopathology, however, unequivocally refuted the blood 
vessel wall as a focus of inflammation. Rather, the biopsy confirmed the presence of 
vasculopathy as opposed to a vasculitis – a clue suggesting that the retinal disease might be 
secondary to a vasculopathy, as well. Recognition that the nature of the retinal disease was 
more likely to be a vasculopathy than a true vasculitis was the final argument leading to the 
rejection of Behcet’s disease.
Additional histopathological features that appeared pertinent, although interpreted as non-
specific, were ischemic necrosis with calcium deposition. The calcifications were present 
even on the CT of the head that had been obtained five months before the hospital 
admission. Dystrophic calcifications, i.e., calcification occurring in degenerated or necrotic 
tissue, are rarely seen after ischemic stroke.18–21 The existing case reports and small case 
series suggest that dystrophic calcifications occur at least weeks, usually months to years 
after the ischemic insult. Accelerated and exaggerated deposition of calcium is typically 
reported in patients with uremia with hyperphosphatemia and/or hypercalcemia, none of 
which had been present in this case.
Was there any other evidence to uphold the hypothesis of the underlying inflammation or 
autoimmunity? First, except for the ophthalmologic condition, his history and physical 
examination were unremarkable, as discussed earlier. Second, there were no signs of 
inflammation in the posterior ocular segment, such as cells in the vitreous, vitreous haze, 
retinal or choroidal inflammatory lesions. Third, laboratory blood testing had not 
demonstrated any clear evidence of inflammatory disease throughout the 6-year disease 
course. Even the notion that the patient’s condition had responded to immunosuppression 
could be disputed. In fact, his had been refractory to numerous immunosuppressive 
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medications. Although the “improvement” in his brain imaging abnormalities with 
dexamethasone had been considered a surrogate marker of cerebral inflammation, similar 
effects can be observed in response to the administration of glucocorticoids in settings 
associated with vasogenic edema from any cause, including primary and metastatic tumors 
as well as high-altitude cerebral edema.22–24
Given the lack of clinical data supporting the hypothesis that the illness was, in fact, due to a 
systemic autoimmune or any other inflammatory condition, we sought an alternative 
differential diagnosis. We performed a PubMed search for the four most prominent features, 
“vasculopathy”, “retinopathy”, “nephropathy”, and “cerebral calcifications.” The first 
matching entity to appear was Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL), 
which is a rare, autosomal dominant condition caused by mutations of TREX1 gene.
RVCL encompasses the following phenotypes or clinical syndromes, named originally 
according to the organ of dominant involvement: hereditary vascular retinopathy (HVR), 
cerebroretinal vasculopathy (CRV), hereditary endotheliopathy with retinopathy, 
nephropathy, and stroke (HERNS), and hereditary systemic angiopathy (HSA). RVCL 
patients typically present in their thirties or forties with vision complaints or neurological 
symptoms, often accompanied by asymptomatic renal insufficiency.1 RVCL is caused by 
heterozygous frameshift mutations in the carboxyl-terminus (C-terminus) of three-prime 
repair exonuclease-1 (TREX1), the major mammalian 3′ to 5′ DNA exonuclease.25 TREX1 
degrades aberrant single-stranded DNA (ssDNA) and double-stranded (dsDNA) molecules 
that are products of reverse transcriptase activity. The aberrant endogenous nucleic acids can 
upregulate type I interferon (IFN) signaling through binding to a DNA sensor cyclic GMP-
AMP synthase (cGAS) in a manner similar to that of viral DNA.26 TREX1 thus functions as 
a negative regulator of interferon-stimulatory DNA (ISD) responses.27
To date, only 12 families and 3 individual patients with RVCL harboring 8 C-terminal 
frameshift mutations have been identified (Table 2).25, 28–38 One out of 3 individual cases 
carried a de novo mutation.32 In RVCL, the mutations alter the intracellular localization of 
the enzyme without impairing its enzymatic activity or causing a toxic gain of function.25 
Mutations that disrupt the enzymatic sites in TREX1 are associated with a variety of 
different syndromes including Aicardi-Goutières syndrome (AGS), systemic lupus 
erythematosus (SLE), and familial chilblain lupus, the pathophysiology of which is distinct 
from RVCL.39 The loss of exonuclease function causes accumulation of the endogenous 
nucleic acids that trigger constitutive upregulation of type I interferon signaling. The three 
conditions are characterized by increased IFN-α as well as other markers of inflammation 
and autoimmunity.
The link between the impairment of TREX1 localization and the vasculopathy in patients 
with RVCL remains elusive. Recently, upregulation of type I IFN–inducible genes in the 
peripheral blood mononuclear cells and normal serum IFN-α levels in a patient with 
mutation-proven RVCL has been described.35 A broader immunological anomaly related to 
dysfunctional microglia that triggers the vasculopathic process has been proposed.1
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The microvasculopathy leads to end-organ damage that initially manifests with retinopathy 
and/or neurological symptoms. Gradually progressive loss of vision is accompanied by 
several features that are indicative of retinal microvascular injury. These include capillary 
obliterations, enlargement of the foveolar avascular zone, cotton-wool spots, telangiectatic 
vessels, and microaneurysms.1, 40 The resulting neovascularization necessitates panretinal 
laser photocoagulation for prevention of vitreous hemorrhage.
Neuroimaging features encompass tumor-like lesions with surrounding vasogenic edema, 
white matter involvement reminiscent of demyelinating disease, and focal 
calcifications.37, 41 Thickened vessels with white matter ischemia, necrosis, and dystrophic 
calcifications are characteristic neuropathological features.1 Renal insufficiency is present in 
about 75% patients. The characteristic histopathological renal abnormality is diffuse 
arteriolopathy with resulting arteriolonephrosclerosis and glomerulosclerosis. Less 
frequently, hepatocellular injury with or without cholestasis and nodular regenerative 
hyperplasia may develop. It thus became apparent that all the elements in this patient’s 
history, ophthalmologic and neurologic examination, neuroimaging, laboratory findings, 
renal and brain histopathology were congruent with the features of RVCL.
In considering the possibility of an autosomal dominant condition, it surfaced again that his 
father had died of Hodgkin’s disease at age when RVCL would have been latent. We also 
note that although the cause of his paternal uncle’s early death in his mid-forties remains 
unexplained, the uncle’s demise was associated with renal failure.
Laboratory Diagnosis
A sample of the patient’s blood was sent for TREX1 gene analysis to Denver Genetic 
Laboratories at Children’s Hospital Colorado. It demonstrated a sequence variant in the 
TREX1 gene, c.830–833dupAGGA that translates into p.Asp278Glufs*48 (D278Efs*48). 
This is a novel heterozygous frameshift mutation in the C-terminus of the protein.
Final Diagnosis
The diagnosis of RVCL was established in this case based on the clinical, imaging, and 
histopathological features, combined with the confirmatory genetic analysis.25
Discussion of Management
The prognosis for patients with RVCL is poor. The disease currently leads uniformly to 
death 5 to 10 years after symptom onset. Therapeutic options are limited. Glucocorticoids 
stall the vasogenic edema and the resulting mass effect, as seen in this patient, but do not 
alter the underlying pathophysiology. The patient, a molecular biologist by training, 
understood the incomplete state of knowledge with regard to RVCL and the poor prognosis 
associated with this diagnosis. Nevertheless, he was committed to pursuing an aggressive 
approach to his disease based on current knowledge.
We initiated therapy with tofacitinib and hydroxychloroquine. This particular drug 
combination was selected for its potential steroid-sparing effects and the possibility that it 
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might target disease-specific mechanisms. Tofacitinib is an inhibitor of Janus kinase 1 
(JAK1), the IFN-α receptor-associated protein tyrosine kinase that is activated by the 
binding of IFN-α to its receptor.42 Tofacitinib is designed to suppress the downstream 
intracellular effects of IFN-α. Hydroxychloroquine, an anti-malarial agent that is known to 
inhibit activation of endosomal Toll-like receptors 7 and 9 by exogenous nucleic acid 
ligands43, has been recently shown to inhibit cGAS and thus block downstream IFN-β 
expression.44 We also continued the patient’s maintenance dexamethasone because the full 
clinical effects of tofacitinib and hydroxychloroquine were expected to require several 
months. Unfortunately, 6 months after the initial hospital admission, the patient’s clinical 
course was complicated by multiple medical issues related to iatrogenic immunosuppression 
(herpes zoster, S. aureus pneumonia), renal failure that eventually progressed to end-stage 
renal disease, hypertensive cardiomyopathy, and atrial fibrillation with several episodes of 
flash pulmonary edema. Our intention to treat him regularly with tofacitinib and 
hydroxychloroquine, unfortunately, was interrupted by intercurrent complications, 
particularly infections, that were likely the result of his longstanding glucocorticoid 
treatment.
Serial brain MRIs demonstrated the absence of tumefactive lesions, but also progression of 
the hemispheric white matter with conspicuous diffuse cerebral atrophy. Nine months after 
the initial hospital admission, he became dependent on others for all activities of daily 
living. Three months later, the patient was bed-bound, unable to communicate, and 
increasingly somnolent. A month later, 13 months after the initial hospitalization, all 
treatments were discontinued in light of his family’s decision to move his care to hospice.
This case precludes any conclusions about the effect of the tofacitinib and 
hydroxychloroquine in management of RVCL. Numerous secondary complications of 
iatrogenic immunosuppression and end-organ damage were already irreversible at the time 
of their initiation. An alternative, potentially therapeutic compound that was recently shown 
to correct defects in TREX1 mutant cells and Trex1−/− knock-out mouse model is 
aclacinomycin.45 The clinical data supporting its use are still lacking. We hope that better 
molecular characterization of the link between C-terminal TREX1 mutations and 
microvasculopathy will help in identification of potential therapeutic targets and defining 
targeted treatments for patients with this rare condition.
Conclusion
In summary, this case is instructive from many perspectives. First, it highlights the principles 
of diagnostic reasoning and reveals several clinical heuristics as sources of cognitive error.46 
The multisystem organ involvement and the retinal abnormalities led to acceptance of a 
rheumatologic, Behçet-like disease. The interpretation of fluorescein angiography as 
indicative of “retinal vasculitis” and “posterior uveitis” led to the faulty assumption that the 
patient’s multi-organ disorder was caused by an inflammatory “-itis”, thereby creating a 
cognitive anchor that precluded the appropriate assimilation of subsequent data. Further, the 
absence of indicators of underlying inflammation in serum and CSF was attributed 
incorrectly to chronic immunosuppressive therapy. Improvement of brain imaging 
abnormalities following the initiation of dexamethasone was considered a surrogate marker 
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of cerebral inflammation. The case thus underscores the importance of re-visiting previous 
assumptions when the various facts do not “add up”. Second, it demonstrates the utility of 
PubMed in diagnosing rare diseases. Finally, this case expands the genetic landscape of 
RVCL and provides the detailed clinical, radiological and histopathological description of 
this rare autosomal dominant condition.1 The callosal involvement has not been described 
previously. The infratentorial lesions observed in this case have heretofore been deemed 
rare.1
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Figure 1. 
Neuroimaging on hospital admission. Axial fluid-attenuated inversion recovery (FLAIR; A) 
magnetic resonance imaging (MRI) of the brain showed a left cerebellar lesion and a right 
temporo-parieto-occipital tumefactive lesion with confluent white matter hyperintensities 
that extended through the splenium of the corpus callosum into the left periventricular white 
matter. Axial diffusion-weighted imaging (DWI; B left) paired with apparent diffusion 
coefficient (ADC; B right) map revealed foci of restricted diffusion. Gadolinium was not 
administered due to renal insufficiency. Computerized tomography (CT) of the head 
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demonstrated punctate calcifications scattered throughout the frontal white matter 
(arrowheads).
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Figure 2. 
Fluorescein angiography of the left eye on admission to our hospital. Extensive retinal 
ischemia with enlargement of the foveal avascular zone (arrowhead), perivascular 
fluorescein leakage (curved arrow), hyperfluorescence of vessel walls (arrows), and 
numerous scars in the retinal periphery from pan-retinal photocoagulation are illustrated.
Vodopivec et al. Page 15
Ann Neurol. Author manuscript; available in PMC 2016 May 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Brain histopathology, hematoxylin and eosin. The white matter has ill-defined areas of 
necrosis with dystrophic calcification, with margins that appear to have ischemic changes 
(A; scale bar: 150 µm). The small blood vessels in the tissue surrounding the areas of 
necrosis have abnormally thickened walls (B, C; scale bar: 75 µm). Other angiomatoid 
vascular proliferations are associated with mild chronic inflammatory infiltrate (D; scale bar: 
40 µm).
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Figure 4. 
Axial FLAIR MRI of the brain following a 10-week course of high-dose dexamethasone. 
Note the prominent decrease in the white matter edema with resolution of the mass effect, 
and postsurgical changes in the right parietal lobe (arrowhead).
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Table 2
TREX1 mutations in retinal vasculopathy with cerebral leukodystrophy
Frameshift Mutation
and References
Reported Syndromes Subjects
V235fs (V235Gfs*6)25,28
  
25,29,30
  
31,32
  
25
CRV
HVR + migraine + Raynaud's syndrome
HSA
not reported
1 family w/ 18 affected members + 2 individual patients
1 family w/ >20 affected members
1 family w/ 5 affected members
2 families, unknown number of affected individuals
T236fs (T236Nfs*5)25,33 CRV 1 family w/ 4 affected members
T249fs (T249Sfs*14)25,34 HERNS 1 family w/ 11 affected members
T270fs (T270Dfs*55)32 HSA 1 individual patient
P275fs (P275Qfs*2)35 RVCL (retina, CNS, kidneys) 1 individual patient, probably brother
D278fs (D278Efs*48) RVCL (retina, CNS, kidneys) 1 individual patient, possibly father and paternal uncle
R284fs (R284Kfs*41)25,36 HERNS 1 family w/ 3 affected members
E285fs (not reported)37 CRV 1 family w/ multiple affected members
L287fs (L287Afs*38)25 not reported 1 family, unknown number of affected individuals
not analyzed38 CRV 1 family w/ 4 affected members
Symptomatic organ involvement: retina in HVR; retina and CNS in CRV; retina, CNS, and kidneys in HERNS; retina, CNS, kidneys, and liver in 
HSA.
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